Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population-Reference-Cited by-同舟云学术

Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population

Published:2024-08-15 Issue:7 Volume:144 Page:790-793
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Muchtar Eli¹^ORCID,Geyer Susan²,Merlini Giampaolo³⁴^ORCID,Gertz Morie A.¹^ORCID

Affiliation:

1. 1Division of Hematology, Mayo Clinic, Rochester, MN

2. 2Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN

3. 3Amyloidosis Research and Treatment Center, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy

4. 4Department of Molecular Medicine, University of Pavia, Pavia, Italy

Abstract

Abstract The survival of patients achieving a cardiac complete response in light chain amyloidosis, defined as N-terminal pro B-type natriuretic peptide ≤350 pg/mL or B-type natriuretic peptide ≤80 pg/mL, was similar to that of a matched general population, with estimated 5-year survival rates of 93% and 95%, respectively.

Publisher

American Society of Hematology

Link

https://ashpublications.org/blood/article-pdf/144/7/790/2237722/blood_bld-2024-024623-main.pdf

Reference15 articles.

1. Systemic immunoglobulin light chain amyloidosis;Merlini;Nat Rev Dis Primers,2018

2. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis;Dispenzieri;J Clin Oncol,2004

3. Treatment of AL amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement 2020 update;Muchtar;Mayo Clin Proc,2021

4. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial;Gertz;Blood,2023

5. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes;Palladini;J Clin Oncol,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Pathophysiological and Therapeutic Implications of Cardiac Light-Chain Amyloidosis Compared With Transthyretin Amyloidosis;JACC: Heart Failure;2024-08

2. Successes in translation;Amyloid;2024-07-02